5ALPHA-REDUCTASE INHIBITORS FOR REDUCTION OF PROSTATE EPITHELIAL CELL GROWTH

5 种减少前列腺上皮细胞生长的α-还原酶抑制剂

• 批准号: 8167834
• 负责人: BRIAN L LINDSHIELD
• 金额: $ 2.37万
• 依托单位: KANSAS STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-07-01 至 2011-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8167834
• 关键词: American; Androgens; Automobile Driving; Benign Prostatic Hypertrophy; Botanicals; Cell Proliferation; Computer Retrieval of Information on Scientific Projects Database; Development; Diagnosis; Dutasteride; Effectiveness; Enzymes; Epithelial Cells; Finasteride; Funding; Grant; Growth; Institution; Malignant Neoplasms; Malignant neoplasm of prostate; Nutrient; Oxidoreductase; Prostate; Public Health; Reporting; Research; Research Personnel; Resources; Sabal serrulata; Sales; Saw palmetto extract; Source; Stanolone; Testosterone; Therapeutic; United States National Institutes of Health; cell growth; combat; implantation; inhibitor/antagonist; male; men; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Prostate cancer is the most commonly diagnosed male cancer. Thus, preventative and/or therapeutic strategies to combat this cancer could have a profound impact on public health. The 5¿-reductase inhibitors finasteride (Proscar¿) and dutasteride (Avodart¿) are commonly used to treat benign prostatic hyperplasia (BPH) but may also potentially decrease the development and/or progression of prostate cancer. 5¿-reductase enzymes convert testosterone to the more potent androgen dihydrotestosterone, which is important for driving the growth of most prostate cancers. Specific Aim 1 will examine the effectiveness of finasteride and dutasteride when begun before or after tumor implantation. Saw palmetto extracts have also been used to treat BPH and are reported to decrease 5¿-reductase enzymes, but there has been a lot of inconsistency their reported effectiveness. Despite the saw palmetto's questionable effectiveness, it is commonly used by Americans, ranking in the top 5 of botanical sales and is commonly used by men with prostate cancer. We believe that the variable results between studies may be due to differences in the extracts nutrient profiles, which have been reported to vary widely. Specific Aim 2 we will collect commonly used commercial saw palmetto extracts and characterize their nutrient profiles. We will then determine whether an extract's nutrient profile correspond to its ability to inhibit 5¿-reductase and cell proliferation of prostate cancer epithelial cells.

该副本是使用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这是调查员的机构。 前列腺癌是最常见的男性癌症。这是对抗这种癌症的预防和/或治疗策略，可能会对公共卫生产生深远的影响。通常使用5埃还原酶抑制剂抑制剂（proscAr®）和dutasteride（avodart？）来治疗良性的前列腺增生（BPH），但也可能有可能降低前列腺癌的发展和/或进展。 5�-还原酶将睾丸激素转化为较大的雄激素二氢睾丸激素，这对于驱动驱动很重要 大多数前列腺癌的生长。特定的目标1将在肿瘤植入后或之后检查非那雄胺和Dutasteride的有效性。 SAW Palmetto提取物也已用于治疗BPH，据报道可降低5—还原酶，但其报道的有效性很大。尽管Saw Palmetto具有可疑的有效性，但美国人通常使用它，在植物销售的前五名中排名，前列腺癌男性通常使用。我们认为，研究之间的可变结果可能是由于提取物养分谱的差异所致，据报道，这些谱图差异很大。具体目的2我们将收集常用的商业锯棕榈提取物，并表征其营养谱。然后，我们将确定提取物的养分特征是否对应于其抑制5-还原酶和前列腺癌上皮细胞的细胞增殖的能力。